Catalysts / EIKN
Upcoming FDA decisions and readouts we track for Eikon Therapeutics, each with the filing that announced it.
FreeBioList tracks 4 upcoming catalysts for Eikon Therapeutics (EIKN, listed on Nasdaq). They cover 3 programmes: EIK1001 (Non-squamous NSCLC (TLR7/8 agonist); Melanoma — first interim analysis), EIK1003 (Advanced solid tumours (PARP1-selective)) and EIK1005 (Advanced solid tumours (WRN helicase inhibitor)).
First on the list: the Phase 2 readout for EIK1001 (Non-squamous NSCLC (TLR7/8 agonist)), guided by the company to H2 2026. The furthest-out event tracked is H2 2026. By stage, the upcoming rows are 2 Phase 1/2 readouts, 1 Phase 2 readout and 1 Clinical readout.
All 4 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Eikon Therapeutics EIKN · Nasdaq | EIK1001 | Non-squamous NSCLC (TLR7/8 agonist) | H2 2026 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | No |
| Eikon Therapeutics EIKN · Nasdaq | EIK1001 | Melanoma — first interim analysis | H2 2026 company guidance |
Clinical readout | Verified | 8-K exhibit 99.1 ↗ | No |
| Eikon Therapeutics EIKN · Nasdaq | EIK1003 | Advanced solid tumours (PARP1-selective) | H2 2026 company guidance |
Phase 1/2 readout | Verified | 8-K exhibit 99.1 ↗ | No |
| Eikon Therapeutics EIKN · Nasdaq | EIK1005 | Advanced solid tumours (WRN helicase inhibitor) | H2 2026 company guidance |
Phase 1/2 readout | Verified | 8-K exhibit 99.1 ↗ | No |
FreeBioList